Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPSMA neoadjuvant radioligand therapy in high-risk localized prostate cancer
jRCT2031250104Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Phase 2, open-label trial of lutetium lu-177 psma-r2 and 225Ac-PSMA-R2 in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs) and Biochemical recurrence-free survival (BFS). Started Jun 2025; status: completed.
02
Drugs
lutetium lu-177 psma-r2225Ac-PSMA-R2
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250104.